amitriptyline has been researched along with Neurally Mediated Faint in 1 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral amitriptyline treatment was given to all patients, with a starting dose of 10 mg once a day." | 2.73 | Preliminary observations on the effect of amitriptyline treatment in preventing syncope recurrence in patients with vasovagel syncope. ( Abali, G; Amasyali, B; Aytemir, K; Bariş Kaya, E; Kabakçi, G; Kocabaş, U; Köse, S; Nazli, N; Oto, A; Ozkutlu, H; Tokgözoğlu, L, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bariş Kaya, E | 1 |
| Abali, G | 1 |
| Aytemir, K | 1 |
| Köse, S | 1 |
| Kocabaş, U | 1 |
| Tokgözoğlu, L | 1 |
| Kabakçi, G | 1 |
| Amasyali, B | 1 |
| Ozkutlu, H | 1 |
| Nazli, N | 1 |
| Oto, A | 1 |
1 trial available for amitriptyline and Neurally Mediated Faint
| Article | Year |
|---|---|
Preliminary observations on the effect of amitriptyline treatment in preventing syncope recurrence in patients with vasovagel syncope.
Topics: Administration, Oral; Adrenergic Uptake Inhibitors; Adult; Amitriptyline; Female; Humans; Male; Seco | 2007 |